Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Orlando, Florida

This page shows live ClinicalTrials.gov search results for Orlando, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
6859
Shown on this page
12
Current sort
Recently updated
Location scope
Orlando, FL
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Orlando, Florida. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 517–528 of 6,859 matching trials in Orlando, FL.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Recruiting No phase listed Observational Accepts healthy volunteers

Driving Time and Facial Skin Hydration Asymmetry in Florida Drivers

NCT07764809
Conditions
Skin Diseases, Photoaging, Skin Hydration
Interventions
BT-Analyze bioimpedance skin hydration measurement
Other
Lead sponsor
IAS Skin Care
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Smoking Cessation
Interventions
AXS-05 (dextromethorphan-bupropion), Bupropion, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
26
States / cities
Little Rock, Arkansas • Lemon Grove, California • Long Beach, California + 22 more
Active, not recruiting Not applicable Interventional

SpaceIT Hydrogel System for Perirectal Spacing

NCT06451614
Conditions
Prostate Cancer
Interventions
SpaceIT Hydrogel System, Commercially available Boston Scientific Spacer
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Laguna Hills, California • Los Angeles, California • Miami, Florida + 18 more
Conditions
Secondary Progressive Multiple Sclerosis (SPMS)
Interventions
Remibrutinib (blinded), Placebo, Remibrutinib (Open label)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Conditions
Gynecologic Cancers
Interventions
Healthy Eating Active Lifestyle (HEAL): Gyn Cancer Program
Behavioral
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Non-alcoholic Steatohepatitis
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
130
States / cities
Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 100 more
Conditions
Major Depressive Disorder
Interventions
Azetukalner, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
45
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 38 more
Conditions
Rectal Cancer Surgery
Interventions
ColoSeal ICD System, Protective Diverting Ostomy
Device · Procedure
Lead sponsor
Averto Medical, Inc.
Industry
Eligibility
22 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Orlando, Florida • Weston, Florida • Columbus, Ohio + 3 more
Conditions
Breast Neoplasms
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Paclitaxel, Nab-paclitaxel, Capecitabine, Liposomal doxorubicin
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
46
States / cities
Chandler, Arizona • Gilbert, Arizona • Fullerton, California + 38 more
Conditions
Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
Interventions
GB-4362, enfortumab vedotin (EV), Pembrolizumab
Drug
Lead sponsor
Generate Biomedicines
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Duarte, California • Irvine, California • Orlando, Florida + 7 more
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 375 mg acetazolamide, Placebo: Negative control
Drug
Lead sponsor
Incannex Healthcare Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
13
States / cities
Chula Vista, California • Brandon, Florida • Jacksonville, Florida + 9 more
Conditions
Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
Interventions
Azetukalner, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
34
States / cities
Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 29 more